Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive save search
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: 185.44%
H: 288.03%
C: 288.03%
arx788 treatment breast positive cancer her2- her2 metastatic breast cancer
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $5.395 -1.19% 250K
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks
Published: 2022-12-08 (Crawled : 12:00) - globenewswire.com
PHVS | $18.19 -1.25% 110K
|
|
| O: 66.93%
H: 184.96%
C: 173.51%
phvs416 treatment positive study
Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022
Published: 2022-04-08 (Crawled : 19:00) - biospace.com/
PHIO | $0.631 -1.07% 23K
|
Health Technology
|
| O: -2.94%
H: 175.0%
C: 167.05%
ph-894 disease positive ph94
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
Published: 2023-09-25 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.489 -2.59% 73K
|
Professional, Scientific, and T...
|
| O: 97.29%
H: 144.27%
C: 94.66%
mc138 ttx-mc138 pre-clinical positive therapeutics results glioblastoma
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138Further Supports TTX-MC138 Application in Brain Cancer
Published: 2023-09-25 (Crawled : 17:00) - biospace.com/
RNAZ | $0.489 -2.59% 73K
|
Professional, Scientific, and T...
|
| O: 97.29%
H: 144.27%
C: 94.66%
mc138 ttx-mc138 pre-clinical positive cancer application therapeutics results glioblastoma
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
Published: 2021-03-01 (Crawled : 12:03) - globenewswire.com
MORF | $27.615 0.38% 170K
|
Health Technology
|
| O: 24.45%
H: 106.67%
C: 88.56%
phase 1 positive results trial phase 3 phase 2
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
JSPR | $22.31 -3.88% 32K
|
|
| O: 210.62%
H: 153.33%
C: 82.67%
treatment disease trial therapeutics positive
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Published: 2022-09-28 (Crawled : 11:00) - biospace.com/
PEPG | $11.34 -4.26% 85K
|
|
| O: 16.92%
H: 111.18%
C: 79.77%
edo51 treatment trial duchenne positive phase 1
Senseonics Announces a Positive Coverage Decision for Eversense CGM from EmblemHealth
Published: 2021-01-19 (Crawled : 17:00) - biospace.com/
SENS | $0.4021 -3.34% 970K
|
Electronic Technology
|
| O: 1.27%
H: 86.25%
C: 78.13%
positive
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
IVVD | $2.3 -2.13% 280K
|
Manufacturing
|
| O: 23.93%
H: 133.17%
C: 77.72%
vyd222 covid-19 positive ongoing trial results
Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia
Published: 2021-04-26 (Crawled : 11:00) - biospace.com/
RVPH | $2.95 -2.32% 99K
|
|
| O: 14.58%
H: 91.92%
C: 75.76%
phase 2 schizophrenia positive results trial trial results
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
Published: 2023-12-12 (Crawled : 21:00) - globenewswire.com
CCCC | $6.56 -5.07% 1.2M
|
Health Technology
|
| O: 35.9%
H: 89.62%
C: 73.27%
cft7455 positive trial therapeutics
Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer's Disease - Patients' Cognition Improved 3.3 Points on ADAS-Cog11
Published: 2021-05-21 (Crawled : 18:00) - biospace.com/
ANVS | $9.69 -1.62% 100K
|
Health Technology
|
| O: 39.81%
H: 165.43%
C: 62.56%
disease alzheimer phase 2 positive alzheimer’s alzheimer's disease alzheimer's anvs401
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
Published: 2024-03-06 (Crawled : 13:30) - globenewswire.com
NXL | $1.41 -4.08% 230K
|
|
| O: -1.61%
H: 95.85%
C: 52.0%
device positive technology results study
Nextleaf Solutions Ltd. Achieves Strong Fiscal Year 2023 Financial Performance, Debt-Free Status, and Positive Cash Flow from Operations
Published: 2024-01-31 (Crawled : 18:00) - biospace.com/
OILFF | $0.1025 15K
|
Process Industries
|
| O: 8.48%
H: 50.0%
C: 49.79%
year positive solutions flow financial
SigmaTron International, Inc. Announces Agreement with Its Secured Lenders and Sale of a Majority Position of Wagz, Inc.
Published: 2023-05-04 (Crawled : 17:00) - globenewswire.com
SGMA | $4.01 1.01% 29K
|
Electronic Technology
|
| O: -1.26%
H: 83.83%
C: 48.94%
agreement
Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia
Published: 2021-06-29 (Crawled : 11:00) - globenewswire.com
CERE | News | $42.125 -0.04% 210K
|
Finance
|
| O: 60.38%
H: 54.22%
C: 47.27%
schizophrenia phase 1 positive results topline trial phase 1b phase 2b
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LIFE | $1.605 -0.93% 95K
|
Health Technology
|
| O: 14.96%
H: 47.46%
C: 45.24%
phase 1 positive trial phase 1b phase 2b response
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response of ATYR1923 in Pulmonary Sarcoidosis
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LIFE | $1.605 -0.93% 95K
|
Health Technology
|
| O: 14.96%
H: 47.46%
C: 45.24%
biopharma phase 1 positive trial phase 1b phase 2b
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.